.Nature Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of individuals along with HER2+ advanced bosom cancer as well as active or steady brain metastases revealed regular intracranial activity and systemic efficiency of T-DXd.